Excellent vaccine news
December 19, 2020
238,326
7,848
3,505
4.76%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around December 19, 2020
See what was published immediately before and after this episode.
32:15Now PlayingExcellent vaccine news
YouTube Description
as posted by the channelPfizer progress
400 GPs, 83 hospitals
Half a million so far
200,000 a day should be receiving jabs, well over one million a week by Christmas
Pfizer orders
50 million doses by end of 2020
US, 100 – 500 million doses
EU, 200 million doses
UK, 40 million doses
EMA, Monday 21st December
Moderna
FDA grants emergency approval
Six million doses ready to go
The end begins just after Christmas
Approved within days of Christmas
Senior Whitehall sources
Medicines and Healthcare Regulatory Agency (MHRA)
28 or 29 December
Final data provided to the regulator on Monday 21st December
Four million doses ready
Football stadia, racecourses, conference centres, pharmacies
First week of January
Several million doses a week
UK, 100 million doses (80 million produced in UK)
India, 50 million doses in stock
First batch of four million doses, Netherlands and Germany
AstraZeneca has 15 million doses of active ingredients ready, filled into vials in days
Two doses, 4 week gap
Leaving an adequate gap between doses is the most crucial way to boost efficacy
Oxford AstraZeneca orders
EU, 400 million doses
UK, 100 million
US, 300 million
China, 200 million
Japan, 120 million
Brazil, 100 million
Indonesia, 100 million
Australia, 33.6 million
Egypt 30 million
Argentina 32 million
Canada 20 million
Argentina and Mexico to produce for Latin America
Vaccines alliance for poorer countries, 300 million
Three billion does in 2021
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses, (Nature Medicine, 17th December)
Viral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222)
190 vaccines currently in development
Neutralizing antibodies against the viral spike protein correlate with protection
Additional antibody functions may also be important in preventing infection
Two jabs, 56 days apart
SD/SD n = 20
SD/LD n = 32
A booster dose is safe and better tolerated than priming doses
After second dose
Increased anti-spike neutralizing antibody titers,
Increased cell mediated immunity
Increased neutrophil and monocyte phagocytosis
Increased complement activation
Increased natural killer cell activation
SD / SD
Stronger antibody responses
T cell responses did not increase with either booster dose
These data support the two-dose vaccine regime that is now being evaluated in phase 3 clinical trials
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.